Data from the LIBERTY AD PRESCHOOL trial, and its ongoing open-label extension analysis show that dupilumab is safe and clinically effective, and can lead to statistically significant symptom improvement among patients aged 6 months to 17 years who have moderate to severe atopic dermatitis (AD).
A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
American Indians and Alaska Native individuals had lower estimates of incidence of diabetic retinopathy than had been reported.
Following the course of lung function in treatment-naïve patients, researchers found that lung function decline does not accelerate prior to mechanical ventilation.
Minnesota looks to create abortion refuge for patients and providers; Moderna’s expected price single dose of COVID-19 sits at $130; FDA staff sees a "clinical benefit" in Biogen’s ALS drug.
On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.
Specific dosing regimens of treatments prescribed by blood specialists have not been widely studied, despite the advent of newer hemophilia therapies, the researchers said.
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discusses the standard of care for the prevention and treatment of primary and recurrent Clostridioides difficile infection (CDI).
A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
Dermatologists recommended biologics at similar rates in scenarios describing Black, Hispanic, and White patients with moderate to severe psoriasis.
Topics to be addressed at the annual conference, which will bring more than 1900 attendees to Kissimmee, Florida, include the Enhancing Oncology Model, efforts to regulate pharmacy benefit managers, and 340B reform.
Baseline risk assessment that includes prior treatment history for cancer, prior cardiovascular events, and markers for potential heart damage are all important, emphasizes Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center in Chicago.
Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.
Candida auris was first reported in the United States in 2016; the highly contagious fungal infection has been labeled an “urgent threat” by the CDC, and its spread may have aided by underresourced public health systems.
The patient received a diagnosis of myasthenia gravis (MG), then underwent a medical odyssey as physicians attempted to pin down the cause of his neurological symptoms.
Gov. Mark Gordon sings a ban on the use of abortion pills in Wyoming; a new study shows that Affordable Care Act has reduced racial disparities in health care; California Gov. Gavin Newsom announces a contract to make affordable insulin.
In a real-world clinical setting, tildrakizumab demonstrated safety and satisfaction among patients with moderate-to-severe plaque psoriasis.
Posters presented at the American Academy of Dermatology 2023 Annual Meeting provided a snapshot of disparities in dermatology care, both in terms of geographic differences in access to care and collection of race/ethnicity data in clinical trials.
A recent study found that chatbot systems that used artificial intelligence (AI) could be valuable in providing access to current, accurate, and complete information about infectious diseases and vaccines against them.
A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.
Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.
Using the DataDerm database has uncovered disparities in prescription patterns, but it’s still early in the process of understanding why those disparities might exist, said Robert Dellavalle, MD, PhD, MSPH, and Ramiro Rodriguez, MD, both of University of Colorado School of Medicine.
Body image dissatisfaction was shown to be the strongest unique contributor for poor quality of life in patients with epilepsy, signaling the potential need for targeted psychological treatments.
Age-specific risk factors for asthma-like symptoms were identified in the first, second, and third years of life, a new study finds.
Right ventricular (RV) dysfunction has previously been linked to symptoms and mortality in pulmonary hypertension (PH), as well as in other conditions, and RV function plays an important role in disease risk and potentially in intensification of pulmonary arterial hypertension treatment.
Once thought of as the result of an imbalance in bodily humors, inflammatory skin diseases are now understood to arise from types of immune responses, opening the door to targeted therapies and personalized medicine, according to speakers at the American Academy of Dermatology 2023 Annual Meeting.
Investigators said the Mortality in TTP Score (MITS) was effective at characterizing the risk of death in patients hospitalized with thrombotic thrombocytopenic purpura (TTP).
Treatable skin diseases in the transgender population can be overlooked and not managed, despite how they can negatively impact quality of life, according to researchers.
Study results indicates that the injectable antiretroviral therapy can benefit patients who are historically underserved and may face treatment barriers, including those with mental illness.
Amid a packed roster of of late-breaking research at the American Academy of Dermatology 2023 Annual Meeting, investigators presented findings from long-term extensions of the Topical Ruxolitinib Evaluation in Vitiligo phase 3 studies.
